The mechanistic target of
rapamycin (mTOR) inhibitor
everolimus is an
antitumor agent known to cause
hyperglycemia. However, the
clinical course of
everolimus-induced
hyperglycemia, its pathophysiological basis, and the treatment strategy are not clear. In this case series report, we present the
clinical course of
everolimus-induced
hyperglycemia in four patients.
Hyperglycemia occurred 3-8 weeks after the administration of
everolimus irrespective of the body mass index (range, 21.3-29.1 kg/m2) or pre-existing diabetes.
Insulin or
insulin secretagogues were required for
glycemic control in most of the patients. Of note, the
hyperglycemia was reversible in all patients, and none of the patients required anti-diabetic agents to achieve adequate
glycemic control after cessation of
everolimus therapy. To investigate the underlying mechanism of
everolimus-induced
hyperglycemia, we assessed insulin secretion and sensitivity by 75 g oral
glucose tolerance test,
arginine challenge test, and/or hyperinsulinemic-euglycemic clamp study using stable
isotope-labeled
glucose tracer in two patients.
Everolimus did not affect
insulin sensitivity in the liver, skeletal muscle, or the adipose tissue. In contrast,
everolimus impaired insulin secretion and thereby increased basal hepatic
glucose production. These findings further our understanding of the role of mTOR in
glucose homeostasis in humans and provide insights for treatment strategies against
everolimus-induced
hyperglycemia.